Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > Pancreatic Cancer Early Detection
Pancreatic Cancer Early Detection

Pancreatic Cancer Early Detection identifier:


Study Contact Information:

Study Site

  • White Plains, NY
    • White Plains Hospital: Contact: by phone (914) 681-2034 or email     

Pancreatic Cancer Early Detection Program

About the Study

This is a study looking at esophageal as a screening for pancreatic cancer in high risk individuals. 

What the Study Entails

Enrolled subjects will undergo Endoscopic (EUS) alternating with Magnetic Resonance Imaging (), every six to 12 months, for up to 5 years.

Study Lead Investigator

Principal Investigator: Joshua P Raff, MD    

This Study is Open To:

People at elevated risk for pancreatic cancer

  • Known carrier of either the or CDKN2A mutation
  • Known carrier of any of the following mutations (, , , , , , P53, , APC, or ) PLUS first or second degree relative affected with pancreatic cancer;
  • Individual with Peutz-Jeghers Syndrome;
  • Familial Pancreatic Cancer, defined as at least two affected relatives with Pancreatic Cancer, who are with each other, and at least one of those affected must be first degree relative to the study subject;
  • Both parents affected, any age:
  • Any first degree relative diagnosed with pancreatic cancer under age 50;
  • Chronic Pancreatitis Syndrome, defined by either PRSS1 or SPINK1 mutations AND appropriate clinical and family history
This Study is Not Open To:

Patients are excluded if they have:

  • any medical condition that contraindicates endoscopy or biopsy
  • any medical condition that contraindicates
  • history of pancreatic cancer, either endocrine or exocrine
  • clinical suspicion of pancreatic cancer, or any previous radiographic or histologic diagnosis of a pre-malignant finding, including IPMN (Intraductal papillary mucinous neoplasm) and PanIN (Pancreatic intraepithelial Neoplasm).
  • diagnosis of dementia
  • uncontrolled, current illness
  • renal insufficiency with serum creatinine greater than 2.0 mg/dl